ANIP
Price
$59.88
Change
-$0.99 (-1.63%)
Updated
Jun 5 closing price
Capitalization
1.43B
61 days until earnings call
EBS
Price
$6.05
Change
-$0.28 (-4.42%)
Updated
Jun 5 closing price
Capitalization
120.07M
67 days until earnings call
Interact to see
Advertisement

ANIP vs EBS

Header iconANIP vs EBS Comparison
Open Charts ANIP vs EBSBanner chart's image
ANI Pharmaceuticals
Price$59.88
Change-$0.99 (-1.63%)
Volume$247.33K
Capitalization1.43B
Emergent Biosolutions
Price$6.05
Change-$0.28 (-4.42%)
Volume$1.08M
Capitalization120.07M
ANIP vs EBS Comparison Chart
Loading...
ANIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANIP vs. EBS commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIP is a Hold and EBS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ANIP: $59.83 vs. EBS: $6.05)
Brand notoriety: ANIP and EBS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ANIP: 61% vs. EBS: 90%
Market capitalization -- ANIP: $1.43B vs. EBS: $120.07M
ANIP [@Pharmaceuticals: Other] is valued at $1.43B. EBS’s [@Pharmaceuticals: Other] market capitalization is $120.07M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIP’s FA Score shows that 0 FA rating(s) are green whileEBS’s FA Score has 1 green FA rating(s).

  • ANIP’s FA Score: 0 green, 5 red.
  • EBS’s FA Score: 1 green, 4 red.
According to our system of comparison, EBS is a better buy in the long-term than ANIP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIP’s TA Score shows that 6 TA indicator(s) are bullish while EBS’s TA Score has 5 bullish TA indicator(s).

  • ANIP’s TA Score: 6 bullish, 4 bearish.
  • EBS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ANIP is a better buy in the short-term than EBS.

Price Growth

ANIP (@Pharmaceuticals: Other) experienced а +2.70% price change this week, while EBS (@Pharmaceuticals: Other) price change was -6.35% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.45%. For the same industry, the average monthly price growth was +14.82%, and the average quarterly price growth was +63.61%.

Reported Earning Dates

ANIP is expected to report earnings on Aug 06, 2025.

EBS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.45% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANIP($1.43B) has a higher market cap than EBS($120M). ANIP has higher P/E ratio than EBS: ANIP (79.85) vs EBS (17.73). ANIP YTD gains are higher at: 8.236 vs. EBS (-36.715). ANIP has higher annual earnings (EBITDA): 107M vs. EBS (-518.2M). ANIP has more cash in the bank: 221M vs. EBS (112M). ANIP has less debt than EBS: ANIP (286M) vs EBS (860M). EBS has higher revenues than ANIP: EBS (1.02B) vs ANIP (487M).
ANIPEBSANIP / EBS
Capitalization1.43B120M1,192%
EBITDA107M-518.2M-21%
Gain YTD8.236-36.715-22%
P/E Ratio79.8517.73450%
Revenue487M1.02B48%
Total Cash221M112M197%
Total Debt286M860M33%
FUNDAMENTALS RATINGS
ANIP vs EBS: Fundamental Ratings
ANIP
EBS
OUTLOOK RATING
1..100
267
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
48100
SMR RATING
1..100
9094
PRICE GROWTH RATING
1..100
6045
P/E GROWTH RATING
1..100
9311
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (55) in the Biotechnology industry is somewhat better than the same rating for ANIP (92) in the Pharmaceuticals Other industry. This means that EBS’s stock grew somewhat faster than ANIP’s over the last 12 months.

ANIP's Profit vs Risk Rating (48) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (100) in the Biotechnology industry. This means that ANIP’s stock grew somewhat faster than EBS’s over the last 12 months.

ANIP's SMR Rating (90) in the Pharmaceuticals Other industry is in the same range as EBS (94) in the Biotechnology industry. This means that ANIP’s stock grew similarly to EBS’s over the last 12 months.

EBS's Price Growth Rating (45) in the Biotechnology industry is in the same range as ANIP (60) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to ANIP’s over the last 12 months.

EBS's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for ANIP (93) in the Pharmaceuticals Other industry. This means that EBS’s stock grew significantly faster than ANIP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIPEBS
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 17 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ANIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSSSX30.23N/A
N/A
Goldman Sachs Small Cap Value Svc
OSPPX6.46N/A
N/A
Invesco SteelPath MLP Alpha Plus R6
JDCRX43.41N/A
N/A
Janus Henderson Forty R
RYDVX6.05N/A
N/A
Royce Dividend Value Svc
UIIFX30.43N/A
N/A
Victory International Institutional

ANIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANIP has been loosely correlated with ORGO. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIP jumps, then ORGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIP
1D Price
Change %
ANIP100%
-1.70%
ORGO - ANIP
47%
Loosely correlated
+0.87%
PRGO - ANIP
40%
Loosely correlated
-1.10%
DRRX - ANIP
38%
Loosely correlated
-6.30%
SNDL - ANIP
31%
Poorly correlated
N/A
EBS - ANIP
29%
Poorly correlated
-4.42%
More

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with HROW. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then HROW could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-4.42%
HROW - EBS
37%
Loosely correlated
-2.68%
AMRX - EBS
36%
Loosely correlated
-0.55%
SIGA - EBS
32%
Poorly correlated
-4.39%
VTRS - EBS
29%
Poorly correlated
-1.63%
ZOMDF - EBS
29%
Poorly correlated
+3.30%
More